Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

GSK plc (GSK)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
1,733.20 -20.60    -1.18%
27/05 - Closed. Currency in GBP ( Disclaimer )
Type:  Equity
Market:  United Kingdom
ISIN:  GB0009252882 
SEDOL:  0925288
  • Volume: 6,131,065
  • Bid/Ask: 1,688.80 / 1,788.00
  • Day's Range: 1,727.60 - 1,752.00
GSK plc 1,733.20 -20.60 -1.18%

GSK plc Company Profile

 
Get an in-depth profile of GSK plc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

90096

Equity Type

ORD

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Contact Information

Address 980 Great West Road
Brentford, TW8 9GS
United Kingdom
Phone 44 20 8047 5000
Fax -
Web www.gsk.com

Top Executives

Name Age Since Title
Iain James Mackay 59 2019 CFO & Executive Director
Emma N. Walmsley 51 2011 CEO & Director
Hal V. Barron 58 2018 Chief Scientific Officer, President of R&D and Director
Manvinder Singh Banga 67 2015 Senior Independent Non-Executive Director
Jonathan Richard Symonds 62 2019 Non-Executive Chairman
Lynn Laverty Elsenhans 64 2012 Independent Non-Executive Director
Anne C. Beal - 2021 Independent Non-Executive Director
Charles A. Bancroft 61 2020 Independent Non-Executive Director
Urs Rohner 62 2015 Independent Non-Executive Director
Harry C. Dietz - 2022 Independent Non-Executive Director
Jesse L. Goodman 70 2016 Independent Non-Executive Director
Laurie H. Glimcher 70 2017 Independent Non-Executive Director
Vivienne Cox 63 2016 Independent Non-Executive Director & Workforce Engagement Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GSK Comments

Write your thoughts about GSK plc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Chemsedine Bendaci
Chemsedine Bendaci Jan 22, 2022 9:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
target price 2290£ according to zone bourse
Reply
1 0
Report
Rachit adlakha
Rachit adlakha Oct 07, 2021 2:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
1st malaria vaccine approved by WHO. hopefully good news for the stock. definitely good for the developing world!
Reply
3 1
Report
Lucas Whipps
Lucas Whipps Sep 28, 2021 10:13AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Been In GSK since February and wearing almost a 15% gain which i'm pretty chuffed about , not sure what you guys think about GSK going into the future but i'm pretty happy with these returns and am thinking about investing in a PRE IPO called SpectrumX which i have seen on the homepage of LSE and the Sunday times. SpectrumXare leaders in proprietary formulations of HOCL, so looks promising for the future of pharmaceuticals. Have not dabbled with Pre IPOS so wanted to see what you guys think?
Reply
3 1
Report
MoonBoi Skooma
MoonBoi Aug 13, 2021 12:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
to the moon!
Reply
1 0
Report
doc gramps
doc gramps Aug 13, 2021 12:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
when?!
Reply
0 0
Report
MoonBoi Skooma
MoonBoi Aug 13, 2021 12:25PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Already mooned now buy back at 1300
Reply
1 0
Report
Mike Bamber
Mike Bamber Jul 28, 2021 7:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Good old GSK. Never fails to disappoint.
Reply
2 0
Report
Mark Silva
Mark Silva Jul 28, 2021 7:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
AMAZING....great news, good earnings...it comes +2% to -0.7%....I`m done, I`m out
Reply
1 0
Report
Old Timer
Old Timer Jul 28, 2021 7:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
As i said before this company does not understand competitive performance - radical change needed - one off hitting earnings forecast does not mean anything
Reply
1 0
Report
MoonBoi Skooma
MoonBoi Jun 23, 2021 3:22AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
setting my buys at 12.5
Reply
0 0
Report
MoonBoi Skooma
MoonBoi Jun 16, 2021 10:15AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GSK will invent the vaccine of immortality
Reply
1 0
Report
Old Timer
Old Timer Jun 14, 2021 7:17AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Will not deliver on results - never does actually - the plans are all nice on paper - but its all just a financial excercise - the forecasts especially on oncology but not only are not real
Reply
0 0
Report
Peter Sauerbier
Peter Sauerbier Jun 11, 2021 6:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
glx is about to split of the consumer division .
Reply
0 0
Report
Pietro de Libero
Pietro de Libero Jun 10, 2021 10:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Stock's been on fire these past 2 days. What's the driver?
Reply
0 0
Report
Mike Bamber
Mike Bamber Jun 10, 2021 10:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Anticipation that the briefing on the proposed split on 25 June will suggest an unlocking of value. GSK is a lame duck in the Covid race and in many other aspects, so also hope that the breakup will trigger bids for the separate businesses.
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email